Bioasis Technologies Stock Forecast, Price & News

0.00 (0.00 %)
(As of 06/21/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume3,940 shs
Average Volume50,135 shs
Market Capitalization$18.76 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BIOAF News and Ratings via Email

Sign-up to receive the latest news and ratings for Bioasis Technologies and its competitors with MarketBeat's FREE daily newsletter.

Bioasis Technologies logo

About Bioasis Technologies

Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the delivery of therapeutics across the blood-brain barrier (BBB); and the treatment of central nervous system disorders, including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-002), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). Bioasis Technologies Inc. has a research collaboration with Aposense Ltd. to focus on the delivery of siRNA into the brain. The company was founded in 2007 and is based in New Haven, Connecticut.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.44 out of 5 stars

Medical Sector

1768th out of 2,105 stocks

Drugs, Proprietaries, & Sundries Industry

10th out of 14 stocks

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Bioasis Technologies (OTCMKTS:BIOAF) Frequently Asked Questions

What stocks does MarketBeat like better than Bioasis Technologies?

Wall Street analysts have given Bioasis Technologies a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Bioasis Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Bioasis Technologies?

Bioasis Technologies saw a increase in short interest during the month of May. As of May 28th, there was short interest totaling 42,200 shares, an increase of 29.8% from the May 13th total of 32,500 shares. Based on an average daily trading volume, of 14,300 shares, the short-interest ratio is presently 3.0 days.
View Bioasis Technologies' Short Interest

When is Bioasis Technologies' next earnings date?

Bioasis Technologies is scheduled to release its next quarterly earnings announcement on Monday, July 26th 2021.
View our earnings forecast for Bioasis Technologies

How has Bioasis Technologies' stock price been impacted by COVID-19 (Coronavirus)?

Bioasis Technologies' stock was trading at $0.1545 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BIOAF shares have increased by 68.3% and is now trading at $0.26.
View which stocks have been most impacted by COVID-19

Who are Bioasis Technologies' key executives?

Bioasis Technologies' management team includes the following people:
  • Dr. Deborah Ann Rathjen B.Sc. (Hons.), Q.C., Ph.D., M.A.I.C.D., FTSE, Exec. Chairman, CEO & Pres (Age 63, Pay $158.31k)
  • Ms. Christine Antalik, Chief Financial Officer (Age 50, Pay $184.5k)
  • Mr. Graeme Dick, Director of Investor Relations
  • Mr. Kim Elton, Director of Marketing
  • Mr. Doug Williams MBA, Exec. VP & Chief Bus. Officer
  • Dr. Mei Mei Tian, VP & Head of External Research
  • Dr. May Orfali, Consultant Chief Medical Officer

Who are some of Bioasis Technologies' key competitors?

What is Bioasis Technologies' stock symbol?

Bioasis Technologies trades on the OTCMKTS under the ticker symbol "BIOAF."

How do I buy shares of Bioasis Technologies?

Shares of BIOAF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bioasis Technologies' stock price today?

One share of BIOAF stock can currently be purchased for approximately $0.26.

How much money does Bioasis Technologies make?

Bioasis Technologies has a market capitalization of $18.76 million and generates $460,000.00 in revenue each year. The company earns $-3,060,000.00 in net income (profit) each year or ($0.05) on an earnings per share basis.

What is Bioasis Technologies' official website?

The official website for Bioasis Technologies is www.bioasis.us.

Where are Bioasis Technologies' headquarters?

Bioasis Technologies is headquartered at 14 Water Street, Guilford CT, 06437.

How can I contact Bioasis Technologies?

Bioasis Technologies' mailing address is 14 Water Street, Guilford CT, 06437. The company can be reached via phone at 203-533-7082 or via email at [email protected]

This page was last updated on 6/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.